Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals' President and CEO, Jack A. Khattar, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in transactions on September 22, 2025.
• He exercised 27,060 employee stock options at an exercise price of $12.98 per share.
• Concurrently, he sold 16,587 shares of common stock at a weighted average price of $47.02 per share, with individual sales ranging from $47.00 to $47.08.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 14, 2024.
• Following these transactions, Khattar directly beneficially owns 1,122,456 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust.
• He also retains 47,940 unexercised employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's an insider sale, it's part of a pre-arranged 10b5-1 plan, which mitigates negative interpretations. The exercise of options at a low price and sale at a high price indicates the CEO is realizing value, which can be seen as a positive for the stock's performance up to that point. The CEO still retains a significant stake.

Positives

• The CEO exercised options at a significantly lower price ($12.98) than the sale price ($47.02), indicating a substantial personal gain and reflecting positively on the stock's performance up to that point.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to immediate negative company news, mitigating potential negative interpretations of an insider sale.
• The CEO retains a substantial direct and indirect beneficial ownership in the company, indicating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct equity stake of a key executive, which can sometimes be perceived negatively by some investors.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing details an insider transaction by a key executive, which is a routine disclosure for publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may view the CEO's sale as a realization of value, potentially influencing their perception of the stock's current valuation.
• The continued significant direct and indirect ownership by the CEO suggests ongoing alignment with shareholder interests.

Key Dates

Recommendation

The filing reports a routine insider transaction under a pre-arranged 10b5-1 plan, involving the exercise of options and subsequent sale of a portion of shares. While an insider sale might typically raise concerns, the 10b5-1 plan context suggests a planned liquidity event rather than a reaction to negative company developments. The CEO still retains a substantial direct and indirect stake. This transaction alone does not provide sufficient new information to warrant a change in investment thesis; therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's performance and outlook.

Keywords

Supernus Pharmaceuticals, SUPN, Jack A. Khattar, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO, Director